CompletedNot Applicable

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

United States35 participantsStarted 2017-06-02

Plain-language summary

This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age * International Myeloma Working Group (IMWG) criteria for the diagnosis of either MGUS or MM Exclusion Criteria: * Unable to provide consent * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3 * Hemoglobin \< 8 g/dL * Women who are pregnant * Prior history of adverse events with conscious sedation

What they're measuring

Percent enrichment of 13-Carbon in the tricarboxylic acid (TCA) cycle intermediates within bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

Timeframe: Up to 1 day

Trial details

NCT IDNCT03119883

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More Monoclonal Gammopathy of Undetermined Significance trials